ArticleDiscover oncology2025
Heterogeneity of the liver cancer tumor microenvironment: mitochondrial metabolism and causal inference through Mendelian randomization.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hepatic stellate cell derived lipid droplets drive protumoral M2 macrophage polarization in hepatocellular carcinoma.Discover oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study presents a comprehensive investigation into the molecular mechanisms of hepatocellular carcinoma (HCC) through an innovative application of Mendelian randomization (MR) analysis, integrated with immune cell profiling and metabolomic assessment.
methodsUtilizing two-sample Mendelian randomization (TSMR) with data from large-scale GWAS studies, including immune cell profiles from the UK Biobank (n = 1629) and HCC cases from a multi-ethnic meta-analysis (775 cases, 1332 controls), we identified significant causal associations between specific immune cell populations, serum metabolites, and HCC risk. This study employed a multi-omics approach, including Principal Component Analysis (PCA), Gene Set Enrichment Analysis (GSEA), to conduct a comprehensive analysis of the liver cancer TME.
resultsOur analysis revealed three immune cell populations significantly associated with HCC development: CD127-expressing CD28 + CDACDB-T cells (OR = 1.31), and unswitched memory B cells measured by both percentage (OR = 1.57) and absolute count (OR = 1.49). We found an increased dispersion of tumor cells in PCA, reflecting adaptive changes due to complex gene regulatory networks. The TYROBP gene was specifically expressed in myeloid cells and enriched in multiple biological pathways. Cell communication analysis revealed significant interactions between T cells and tumor cells.
conclusionThis study provides a comprehensive view of the heterogeneity of the liver cancer TME and reveals the potential roles of key genes and cell types in the development of liver cancer. These findings offer new insights into the molecular mechanisms of liver cancer and may aid in the identification of new therapeutic targets and biomarkers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.